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Abstract 
Introduction: Overactive bladder (OAB) syndrome is common in the general population, particularly 
in elderly patients. Antimuscarinic drugs (AMs) are considered the mainstay pharmaceutical treatment 
of OAB whereas β3-adrenoceptor agonists, such as mirabegron, represent a good alternative. Owing to 
the important role of muscarinic and β3 receptors in cardiovascular (CV) tissue and to the fact that 
OAB patients often have CV comorbidities, the safety-profile of these drugs constitute an important 
challenge.  
Area covered: The aim of this review is to evaluate the CV effects of AMs and mirabegron in OAB.   
A systematic literature search from inception until December 2017 was performed on PubMed and 
Medline.  
Expert opinion: AMs are generally considered to have good CV safety profile but, however, they may 
cause undesirable adverse events, such as dry mouth, constipation. CV AEs are rare but noteworthy, the 
most common CV consequences related to the use of these drugs are constituted by an increase in HR 
and QT interval. Mirabegron has similar efficacy and tolerability to AMs but causes less adverse 
events, with either modest hypertension and modest increase in HR (<5 bpm) being the most 
commonly reported. 
 
 
 
Keywords: antimuscarinics, cardiovascular adverse effects, heart rate, heart rate variability, 
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Article highlights: 
• Overactive bladder (OAB) is a syndrome characterized by urinary urgency, with or without 
urgent urinary incontinence (UUI), and is usually associated with increased daytime frequency 
and nocturia. OAB often involves elderly people, who often present various cardiovascular 
(CV) comorbidities. 
• Antimuscarinics (AMs) represent the most commonly used drugs in the context of OAB. Eight 
different drugs are currently marketed for pharmacological management of OAB: darifenacin 
hydrobromide, fesoterodine fumarate, imidafenacin, oxybutynin chloride, propiverine 
hydrochloride, solifenacin succinate, tolterodine tartrate and trospium chloride. 
• The most common CV adverse effects associated with the use of AMs are represented by 
increase in heart rate (HR) and QT interval prolongation. Only three cases of serious QT 
prolongation and polymorphic ventricular tachycardia (TdP) were reported with the use of 
solifenacin. 
• Mirabegron, a selective β-3 adrenoceptor agonist represents a good alternative for the treatment 
of OAB. Mirabegron presented similar efficacy and tolerability to AMs in phase II and III trials, 
but with reduced side effects characterized by modest hypertension and an increase in HR < 5 
bpm. 
• The potential impact of AMs and mirabegron on cardiac function should be taken in 
consideration by physician especially in older patients who are likely to present CV risk factor 
and other comorbidities. 
• Despite the safe pharmacological profile of AM drugs and mirabegron, a clinical and ECG 
monitoring might be useful especially in selected patients such as those aged> 80 years or with 
CV comorbidities. 
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1. Introduction  
Overactive bladder (OAB) syndrome is characterized by urinary urgency, with or without urgency 
urinary incontinence (UUI), and is usually associated with increased daytime frequency and nocturia 
[1]. OAB is a common condition worldwide: in Europe, Canada, the United States and Japan, 
epidemiologic studies have reported a prevalence of 8.0% to 16.5% in adults, with rates similar in men 
and women [2,3]. It should be borne in mind that OAB is a heterogeneous condition with a 
multifactorial underlying pathophysiology.  
Various measures may be used to generally improve this condition and to prevent worsening. These 
may include bladder training, pelvic floor muscle exercises, and lifestyle modifications [4]. 
Pharmacological therapy is second-line treatment. Antimuscarinics (AMs) are still the main drugs used. 
However, they have a conspicuously low compliance rate, as they often cause adverse effects (AEs) 
such as dry mouth, constipation and blurred vision [5,6]. Mirabegron, the only β3-adrenoceptor agonist 
approved for clinical use, has an efficacy comparable to that of AMs, but has a better safety profile, 
often similar to that of placebo [7]. In fact, as OAB often involves elderly people, who may have 
various cardiovascular (CV) comorbidities [8], a good safety profile is necessary. Anyway, both 
muscarinic and β-adrenergic receptors are present in both the CV and urinary systems [9]. 
Consequently, drugs that interact with these receptors have to necessarily exert CV effects. The issue of 
the CV safety of these drugs has therefore aroused great interest. The aim of this systematic review is to 
analyze the CV AEs of drugs administered for the treatment of OAB. 
 
2.  The role of muscarinic and β receptors on the regulation of cardiac function 
2.1 Muscarinic receptors  
The heart presents various subtypes of muscarinic receptors: M1, M2, M3 [10]. Among them, the 
activation of M2 receptors plays the most important role.  
In the human heart, M2 receptors can be found not only in the sino-atrial (SA) and atrio-ventricular 
(AV) nodes, but also in other sites such as the endocardium, epicardium, and T-tubules of atrial and 
ventricular cardiomyocytes [11]. M2-mediated stimulation results in the inhibition of the intrinsic rate 
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of firing of pacemaker cells; therefore, heart rate (HR) decreases and AV conduction reduces. 
Furthermore, M2 modulation may also reduce atrial and ventricular contractility [11,12].  
Conversely, the role of M1 and M3 receptors is still not fully understood. M1 receptors are localized in 
the SA node. Indeed, the activation of M1 receptors in both humans and animals can increase HR, and 
this could explain why low doses of AMs may induce paradoxical tachycardia [11]. M3 receptors are 
widely expressed; they can be found in the SA node, the AV node and the ventricles. Their activation 
may influence both the pace-making activity of the SA and AV nodes and the regulation of cardiac 
muscle contractile activity by shortening action potential duration [13,14]. Abramochkin et al. [15] 
have demonstrated, in the murine heart, that M3 stimulation of the SA node reduces pacemaker activity, 
consequently, causing HR decrease. Anyway, these effects are very modest when compared with M2-
response but may play a role in pathological condition such as heart failure, ischemia or atrial 
fibrillation owing to an increased number of this receptor subtype and to a decrease in M2 receptors; 
thus, the role of these receptors is therefore not insignificant [16]. In these conditions, M1 and M3 
receptors may increase automaticity and contractility through a phospholipase c (PLC) dependent 
mechanism that enhances activity of L-type calcium Channel (LTcc) [17]. Furthermore, Lamping et al. 
have shown that M3 receptors may dilate coronary arteries in mice; however, in humans, this effect is 
unclear [18].   
 
 
2.2 β-adrenoceptors 
Conversely, distribution and function of β3 –adrenoceptors remain controversial. Anyway, β3 –
adrenoceptors have been identified in various tissues in both humans and other species [19, 20]. 
In human bladder, β3 –adrenoceptors constitute 97% of total β –adrenoceptor messenger RNA (21). 
They may therefore be considered the main subtype receptor that mediates relaxation of detrusor 
smooth muscle during the storage phase.  
On the other hand, all three adrenoceptor subtypes (β1, β2, β3) are expressed in the CV system, given 
rise to potential concerns about the CV effects of β –adrenoceptors agonists. For what regards β 
receptors, the general consensus is that β1 and β2 adrenoceptors coexist in the human heart, with the 
β1-adrenoceptor predominating with a ratio of approximately 70:30 in the atria and 80:20 in the 
ventricles [22]. HR, contractile force and transmission velocity through the AV node are increased by 
β1- mediated effects [23]. 
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β2 receptors have similar effects. They play an important role in pathologic conditions such as 
congestive heart failure, when β1 receptors density and function are markedly reduced. By contrast, β2 
receptor function remains unaffected [23].  
The β3 receptor is functionally different from β1 and β2 receptors, and its stimulation could activate 
different intracellular pathways depending on the cellular context and on the grade of tissue receptor 
expression [24]. In ventricular myocytes β3 receptors expression is low and its activation is linked to an 
inhibitory intracellular pathway [25].  By contrast, in atrial tissue, in which β3 receptors are more 
expressed, their stimulation is linked to an activating pathway and so increases contractility [25]. 
However, in ventricular myocytes, the grater expression of β1 and β2 receptors minimizes the negative 
inotropic effect of β3 receptors. The impact of β3 receptor on HR is still unclear; receptor stimulation at 
the level of the SA node may activate two different pathways: one mediated by adenylate cyclase, 
which increases automaticity, and another mediated by nitric oxide synthase/guanylate cyclase, which 
exerts an opposite action [26]. Sterin Borda et al. [27] suggest that β3 receptor stimulation leads 
primarily to a positive chronotropic effect while guanylate cyclase pathway is activated later and exerts 
a negative feedback on the adenylate cyclase pathway. Thus, at present, the few available reports on the 
physiological role of β3 receptors are sometimes discordant. This has made clinical development of a 
β3-agonist such as mirabegron a challenge. 
 
3.Cardiac effects of OAB drugs 
3.1   Cardiac effects of antimuscarinic drugs 
The main CV effects of AMs are increased HR, hence tachycardia and palpitations, and decreased HR 
variability (HRV) (Table 1). Therefore, if AMs are prescribed it is advisable to monitor HR and HRV 
especially in older patients and in presence of CV comorbidities [28]. 
AMs may induce increase HR because of the M2 cardiac receptor block caused by these drugs. The 
effect on HR is marked in case of those drugs that do not have high M3 selectivity, implying that they 
significantly inhibit M2 receptors, too (Figure 1). According to several studies, tachycardia is an 
independent CV risk factor and can trigger ventricular arrhythmias [29]. Moreover, reduced HRV 
(which represents the heart response to the activity of the autonomic nervous system and may be 
considered an indicator of hypervagal tone) may increase the risk of myocardial infarction, dangerous 
arrhythmias, cardiac mortality and death from other causes in general population [30]. 
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It has been found that elevated resting HR is a prognostic negative factor not only after myocardial 
infarction but also in patients with heart failure and is closely associated with all cause- mortality in 
general population and particularly in hypertensive subjects [31,32]. Various mechanisms may be 
involved, including heightened arterial wall stress, increased blood pressure, impaired arterial 
compliance and the increased instability of atherosclerotic plaques [33]. Moreover, tachycardia may 
both raise cardiac oxygen demand and at the same time, lower the cardiac oxygen supply by shortening 
the diastolic phase. In a healthy heart this might be of little relevance, while in elderly patients or those 
with CV comorbidities, it could be a risk factor. 
Furthermore, prolongation of the QT interval, induction of polymorphic ventricular tachycardia (TdP) 
and sudden cardiac death may occur in patients treated with AMs. However, QT prolongation and its 
consequences cannot be attributed to the direct activity of AMs but may be an indirect effect due to the 
inhibition of the rapid component of the delayed rectifier potassium current (Ikr), thereby blocking the 
human Ether-a-go-go-Related Gene (hERG) potassium channel in the heart [34]. This term is used to 
indicate the protein or channel derived from the homonymous gene, which determines an increase in 
the time of repolarization and thus in the QT interval. A drug with antagonist activity on hERG channel 
may prolong QT interval by modifying the activity of ion channels on the surface of cardiac myocytes, 
consequently inducing an intracellular Ca 2+overload, thereby giving rise to fluctuations in the electric 
membrane potential [35]. These variations can, in a dose-dependent manner, cause early after-
depolarizations (EADs), which constitute a major trigger of re-entrant ventricular arrhythmias, such as 
Torsade de pointe (TdP) [35]. This arrhythmia is self-limiting but, in some cases, might degenerate into 
ventricular fibrillation.  
Furthermore, in the clinical scenario, these drugs, even at low doses, might interact with other factors 
that can cause QT prolongation, such as hydro-electrolytic disorders (hypokalemia, hypomagnesemia), 
genetic predisposition or diseases. An interesting finding is that women are at higher risk of developing 
drug-induced QT prolongation and drug-induced arrhythmias than men [36,37]. While major 
differences may be found between men and women [38], the underlying mechanisms responsible for 
this predisposition of women are not completely understood.    
 
3.2 Adverse cardiovascular effects of mirabegron  
Mirabegron is a potent agonist of the human β3 adrenoceptor. However, in vitro and in vivo studies 
have also shown effects on β1 adrenoceptors [39,40].    
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Oral administration of mirabegron has been seen to increase HR in dogs and humans [41,42]. This 
effect is dose-dependent, and much more evident at supra-therapeutic doses [43]. 
Mirabegron is able to increase HR to a far higher degree in dogs than in men, according to Korstanje et 
al. [44]. This effect is partly mediated by cross-activation of the β1-adrenoceptor, as mirabegron has a 
greater affinity toward canine β1-receptor [45]. Likewise, mirabegron could increase systolic blood 
pressure by increasing β1 inotropic effects. However, in one study on dogs, mirabegron was associated 
with a decrease in SBP; this could be partially due to the presence of β3 receptors in the vascular 
system in dogs, which could explain a vasodilatory effect. Alternatively, it could be the result of β3 
negative inotropic effects. However, this mechanism is not clear and further studies are needed [46]. 
On the other hand, Mo et al. [39] demonstrated that mirabegron increases the force of atrial contraction 
by activating β1–adrenoceptors, but not β3–adrenoceptors. The effect was indirect, possibly owing to 
the release of adrenaline. Additionally, a separate nonspecific depressant effect on the contractile 
function of the atrium has also been demonstrated in the presence of a β1-adrenoceptor antagonist 
(which was not mediated by β2 or β3-adrenoceptors) [44]. The reason for this effect remains to be 
completely clarified. 
Although pharmacological mechanisms of mirabegron on inducing CV effects are not fully understood, 
an experiment study conducted by Van Gelderen et al [47] in human healthy volunteers has shown 
interesting results. In this study, the administration of a supratherapeutic dose (200 mg) of mirabegron 
in combination with the β1 selective antagonist bisoprolol or the β1/ β2 antagonist propanolol showed 
in both cases a reduction in mirabegron positive chronotropic and hypertensive effects suggesting that 
these are at least partly mediated by β1 receptor stimulation. Moreover, results of this studies do not 
support the hypothesis that pure β3 receptor stimulation has a negative inotropic effect. 
Similarly to AMs, mirabegron may act on the QT by blocking the hERG channel. However, no cases of 
TdP have been reported and, according to an interesting review from our group, the finding of QT 
prolongation >500 msec is a very rare event [42]. In dogs, at exposures 6.5-fold higher than the 
maximal registered human dose (MRHD), the QT interval (when adequately corrected for HR increase 
using Fridericia correction method, QtcF) has not displayed prolongation [44]. In analyses conducted 
on isolated perfused canine ventricular tissue, mirabegron has neither shown effects on potassium 
channels, sodium channels, or calcium channels, nor caused any delay in cell repolarization at doses 
ranging from 4.5- to 24.5-fold higher than the Cmax observed at the MRHD [48]. 
 
4.Clinical studies 
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4.1 Clinical studies on AMs 
The AM drugs currently available for OAB treatment are darifenacin hydrobromide, fesoterodine 
fumarate, imidafenacin, oxybutinin chloride, propiverine hydrochloride, solifenacin succinate, 
tolterodine tartrate, and trospium chloride [49].  
4.1.1 Heart rate and HRV 
In the literature, the AMs that exert the greatest effects on HR are tolterodine, fesoterodine, propiverine 
and trospium [28]. 
Tolderodine is not selective for a muscarinic receptor subtype and may therefore cause cardiac effects 
by stimulating M2-subtype receptors [50].   
In a prospective 7-day exposure, 3-way crossover randomized placebo-controlled trial conducted by 
Olshansky et al. [51] involving healthy subjects over 50 years old, tolterodine (4 mg), darifenacin (15 
mg) and placebo were evaluated with regard to changes in HR. This study showed that, although 
marked changes in HR (>10 bpm) were similar across the three groups, the treatment with tolterodine 
was associated with a significantly higher mean 24-hour HR and a significantly higher minimum HR 
compared with darifenacin. Furthermore, in the same study, tolterodine was associated with a 
significant reduction in HRV, which is an important predictor of cardiac and all-cause mortality. 
The issue of increased HR was also investigated in a post-marketing prospective randomized controlled 
open-label study conducted by Hsiao et al. [52] in 21 women, in which tolterodine was significantly 
associated with an increase in HR after 4, 8 and 12 weeks. This finding was confirmed in a placebo-
controlled study on 30 women, in which tolterodine at doses of 4 mg and 8 mg were associated with 
HR increase compared with placebo. Moreover, tolterodine (8 mg) also reduced HRV in comparison 
with placebo [53].  
Fesoterodine is another AM that has been correlated with an increase in HR. In a randomized double-
blind multi-center placebo-controlled trial conducted on 836 patients, treatment with fesoterodine was 
correlated with a mean increase in HR of 3.3 bpm and 3.9 bpm at doses of 4 mg and 8 mg, respectively, 
in comparison with placebo (0.8 bpm) [54]. Similar results emerged in another double-blind trial, in 
which the mean change in HR was 1 bpm for placebo, 3 bpm for fesoterodine at 4 mg, and 4 bpm for 
fesoterodine at 8 mg [55]. 
Regarding propiverine, in a randomized double-blind, placebo-controlled, crossover study, two doses 
(20 mg q.d and 15 mg t.i.d) of this drug were compared with placebo and oxibutynin. It emerged that 
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both regimens had clear effects on HRV and mean HR, while oxibutynin had a similar effect to that of 
placebo [56]. 
In the American prescribing information, trospium (20 mg) immediate release (IR) is related to an 
increase of 9 bpm in HR, while the extended release (ER) formulation has been associated with an 
increase of 3 bpm [57]. In an interesting review, Guay et al. [58] observed that trospium (100 mg) was 
able to increase HR by 18 bpm. 
On opposite, darifenacin, imidafenacin, oxybutynin and solefinacin have not shown any clinically 
significant effect on HR [59-62] 
 
4.1.2 QT prolongation and TdP 
Four AMs have shown hERG inhibition in in vitro studies: solifenacin, tolterodine, oxibutinin and 
propiverine [63,64]. However, clinically significant episodes were only seen with solifenacin. In 
September 2016, solifenacin was re-categorized as having a possible risk of TdP, which means that the 
drug is associated with QT interval prolongation, albeit in rare cases. However, there is no evidence of 
this effect when it is taken as recommended [65]. 
In the MILAI study, a multi-center open-label phase-IV study, 2.4% of patients who had taken 
solifenacin at 2.5 mg or 5 mg had a QTcF interval over 450 ms at the end of treatment, and 1.4% 
displayed a 30 - 60 ms increase in QTcF duration from the baseline [66]. The Symphony Study found a 
slight increase in mean QTcF following 12 weeks of solifenacin at 2.5mg, 5 mg or 10 mg/day [67]. 
Three cases of QT prolongation and TdP in patients using solifenacin have been reported in the 
literature. The first case involved an 81-year-old woman in whom the QT interval was normal prior to 
the prescription of solifenacin (QT 400 ms; QTc 360 ms); after two weeks of therapy with solifenacin 
(5 mg/day), she suffered a syncopal episode. An ECG recorded immediately after the event revealed 
marked QT prolongation (QT 600 ms; QTc 580 msec). After nine days, new episodes of TdP and 
syncope occurred, prompting interruption of solifenacin treatment; after withdrawal of the drug, ECG 
revealed a markedly shortened QT (QT 500 msec; QTc 408) [68]. 
The second case, described in 2012, concerned an 81-year-old woman who developed recurrent 
episodes of syncope and TdP requiring resuscitation. At the time, she was on therapy with solifenacin 
(10 mg/day) and antiarrhythmic cibenzoline to control atrial fibrillation. ECG showed a prolonged 
repolarization time (QT 680 ms; QTc 660). Following the withdrawal of solifenacin, the QTc interval 
decreased to 458 ms. In this case, however, a synergistic action of cibenzoline and solifenacin may 
have played a role in prolonging QT [69]. 
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The third case occurred in 2015 and concerned an 84-year-old male who had taken solifenacin (10 
mg/day) for 15 days.  It was taken to hospital owing to episodes of syncope and sustained ventricular 
tachycardia. Following resuscitation, ECG revealed QT prolongation (QTc 548 ms); three days after 
solifenacin withdrawal, the QT interval was 420 ms and TdP did not recur [70].  
There is no published evidence that solifenacin blocks the hERG channel. However, this drug enhances 
the late calcium transient current and causes EADs in human induced stem cell-derived cardiomyocytes 
[71].  
Another AM drug that was related with different reports of TdP is terodiline. This drug is an hERG 
channel inhibitor that was associated with QTc prolongation in a concentration dependent manner. Due 
to this fact and to different reports of cardiac dysrhythmia including advanced atrio-ventricular block, 
TdP and ventricular fibrillation, it was withdrawn in 1991 [72,73]. The withdrawal of this drug might 
be also due to the finding of an increased dispersion of the ventricular repolarization duration, which 
has an important pro-arrhythmic role [72]. 
In vitro studies have shown that tolterodine is a blocker of hERG and that prolongs the action potential 
duration (APD) [63]. However, despite its widespread clinical use, no significant correlation with QT 
prolongation and TdP has been found either in clinical trials or in post-marketing surveillance [52, 
74,75]. Furthermore, these effects have not been demonstrated in poor metabolizers, in whom drug 
concentrations are higher. IKr channel affinity of tolterodine is similar to that of dofetilide [63], which 
is included in the “QT drug list” and is clearly correlated with QT prolongation and TdP. 
The fact that a potent block of the hERG channel in vitro did not translate into clinically significant QT 
prolongation could be explained by the contemporary block of LTcc, which partly counteracts the QT-
prolonging effect of IKr block [63] 
With regard to other AMs, in vitro and in vivo findings are concordant: for what concerns propiverine, 
in vitro and in vivo studies on guinea pig [64] and human heart tissue [76] have demonstrated that this 
drug not only blocks the hERG channel but also slowly activates IKr, LTcc and inward rectifying K 
current (IK1), resulting in APD reduction. In a double-blind randomized placebo-controlled study on 
healthy women, propiverine did not show statistically significant QT prolongation [76]. Oxybutynin, 
another hERG blocker, acts like propiverine by blocking IK1 and LTcc, and tends to reduce rather than 
prolong APD. Indeed, in a study conducted on elderly subjects with incontinence found no association 
with QT prolongation [77]. 
 
4.2 Clinical studies on mirabegron 
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The CV safety-profile of mirabegron, the only clinically available β3-adrenoceptor agonist, appears to 
be good and comparable to that of AMs. This drug has been approved for the treatment of OAB in 
Europe, the USA, Canada and Japan [78]. 
Anyway, it may present unwanted CV AEs, such as increased blood pressure, HR, pulse rate (PR) and 
QT prolongation. A recent drug-use results survey assessing the safety of mirabegron in approximately 
10,000 patients confirmed statistically significant benefits in quality of life and symptom questionnaire 
scores. Physicians judged this drug to be “effective” in 80.7% of patients, while 63.6% of patients 
achieved a minimal 3-point clinically important change from the baseline in the mean Overactive 
Bladder Symptom Score [79]. 
In an interesting prospective study regarding the efficacy and tolerability of mirabegron on an 
unselected patient population in daily clinical practice, Balachandran et al. [80] found that mirabegron 
brought significant benefits in quality of life and symptom questionnaires. The study showed that 
mirabegron may be more effective in patients who have less severe symptoms prior to treatment. It has 
low AEs and is well-tolerated. However, although the benefits are not striking, the rate of 
discontinuation owing to AEs is low. Furthermore, a real-world, post marketing, prospective, 
observational study showed that treatment with mirabegron was judged “effective” in 83.3% of patients 
and “ineffective” in 16.7% of patients [81]. 
This was the first prospective clinical study involving patients with current or previous CV disorders, 
while in the registration studies assessing the efficacy and safety of mirabegron, patients with major 
CV pathologies, prolonged QT interval or those taking drugs that could cause prolonged QT had not 
been enrolled. 
 
4.2.1 Heart rate effects and tachycardia events 
This review shows that the use of mirabegron is associated with a modest increase in PR and HR (Table 
2).  
In a phase-II dose-ranging study (DRAGON) of mirabegron, only a slight, but statistically significant, 
increase in PR versus placebo emerged at supra-therapeutic doses of 100 mg and 200 mg, while at 
doses of 25 mg and 50 mg, differences were not statistically significant [82]. 
In a multicenter, randomized, double-blind, parallel-group, placebo and active-controlled, Phase-2, 
proof-of-concept study (BLOSSOM trial), mirabegron (150 mg) immediate release was associated with 
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an increase of 5 bpm in PR from the baseline versus placebo, while for mirabegron (100 mg) IR and 
tolterodine ER, a significant difference vs placebo did not emerge [83]. 
A thorough study of QT/QTc on healthy volunteers [84] revealed that mirabegron has tendency to 
prolong QTc in female patients at supra-therapeutic doses (200 md daily). However, in subsequent 
phase-III clinical trials, mirabegron was well tolerated and, although no serious CV AEs were 
observed, slight, but statistically significant, increases in HR (1 bpm) were reported. On withdrawal of 
the drug, however, these AEs were reversed.     
Overall, for what regards changes in HR elicited by mirabegron, these were more apparent in young 
healthy volunteers than among patients with OAB. This observation was attributed to the higher 
sensitivity of cardiac β–adrenoceptors (probably of the β1-subtype) than in older individuals and in 
those with OAB. 
On analyzing pooled results of three 12-week placebo-controlled phase III trials (SCORPIO, ARIES 
and CAPRICORN), Nitti et al. [85] found that mirabegron was associated with a small rise in HR 
versus placebo; this effect was dose-dependent and reversible on discontinuation of treatment. 
Specifically, the median increase from baseline elicited by mirabegron at 25 mg, 50 mg and 100 mg 
was 1.3 bpm, 1.4 bpm, 2.3 bpm for morning measurements, and 0.2 bpm, 0.6 bpm, and 1.9 bpm for 
afternoon measurements, respectively. Tachycardia events (PR > 100 bpm) in mirabegron groups was < 
5% and, thus, comparable to those observed on placebo and tolterodine. 
In the 12-month phase III safety study TAURUS, a small dose-dependent increase in HR from baseline 
(< 2 bpm) was recorded, which was comparable to that elicited by tolterodine [86]. Tachycardia events 
occurred in 1.0 % and 2.3% in patients receiving mirabegron at 50 mg and at 100 mg, respectively, and 
in 3.1 % of patients receiving tolterodine. 
In a randomized, double-blind, phase IIIb, non-inferiority study (BEYOND), mirabegron (50 mg) was 
associated with a mean increase in HR of 0.45 bpm from the baseline [87]. 
In the non-Japanese Asians OAB study, mirabegron (50 mg) elicited a slight increase in PR six hours 
after administration; this was smaller than in the tolterodine (4 mg) group (1.57 bpm vs 2.72 bpm) [88]. 
In another phase III study, conducted in Japan, a slight 2-bpm increase in PR was observed after 4-
week administration of mirabegron (50 mg) versus placebo. Again, this effect was reversible and PR 
returned to its baseline value 2 weeks after the drug had been withdrawn [89].  
 
4.2.2 Blood pressure and hypertensive events 
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The use of mirabegron is associated with a modest increase in blood pressure and hypertensive events 
(Table 3). 
As emerged from a review by our group [42] that analyzed the pooled results of 12-week phase III 
trials and the results of a 12-month phase III trial, the mean difference in blood pressure at the end of 
treatment versus placebo was not clinically relevant, being below 1 mmHg for the mirabegron doses 
tested. Hypertensive events in the pooled 12-week phase III trials declined as the dose of mirabegron 
increased, being 12%, 8.7% and 6.2% at doses of 25 mg, 50 mg and 100 mg, respectively. No 
statistically significant differences in hypertensive events emerged versus placebo and tolterodine at 4 
mg [85]. 
Similar results were found on analyzing hypertensive events in the 12-month phase III trial, in which 
hypertensive events were recorded in 11% and 10% of patients in the mirabegron 50 mg and 100 mg 
groups, respectively. In addition, in this case, the differences in incidence versus tolterodine (11%) 
were not statistically significant [86]. 
In the non-Japanese Asian OAB trial, the incidence of hypertension was 0.5% in the mirabegron 50 mg 
group and 0.8% in the tolterodine ER 4 mg group. The adjusted mean differences from placebo in SBP 
and DBP were also similar in the two groups [88]. 
In the QT/QTc study, mirabegron (50 mg) was associated with mean increases of 4 mmHg and 1.6 
mmHg in SBP and DBP, respectively, versus placebo [85]. 
 
4.2.3 QT prolongation 
It has been evaluated the association between mirabegron and QT prolongation (Table 4). 
In the pooled 12-week population, the frequency of QTcF prolongation in mirabegron treatments 
groups was <0.4%, and it was comparable to that recorded in placebo and tolterodine groups. 
Moreover, a serious increase in QT (> 500 msec or increase of 60 ms from baseline) occurred only in 5 
patients in mirabegron groups. This study did not reveal any difference between genders in terms of the 
frequency of QT prolongation [85]. In a 12-month trial, QT prolongation >450 ms was seen in 4.9% 
and 3.9 % at mirabegron doses of 50 mg and 100 mg, respectively. These values were similar to that 
recorded in the tolterodine group (4.4%), and QT prolongation was more frequent in females than 
males. Less than 0.4% of patients in both treatment groups suffered serious QT prolongation [86]. 
In a randomized placebo and moxifloxacin-controlled study conducted on 352 healthy individuals of 
both genders, mirabegron caused QT prolongation only at the supra-therapeutic dose of 200 mg, while 
mirabegron at 50 mg and at 100 mg did not elicit any major increase [84]. Furthermore, in the non-
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Japanese Asian OAB study, QTc prolongation occurred in 0.8% of patients treated with mirabegron at 
50 mg; in none of these cases did QTc reach more than 480 ms [88]. 
In the studies analyzed, no cases of QT prolongation were associated with TdP. 
 
4.3 Combination therapy with a beta 3 agonist associated to an AM drug 
The concept of combining two drugs with different modes of action may be used in clinical practice to 
improve symptoms severity and health related quality of life in patients whose symptoms are not 
controlled with monotherapy. The advantage of this choice in terms of safety is the reduction of single 
drugs dosage and of their dose dependent AEs in consideration of synergistic drugs action.  
A 12-week randomized placebo-controlled double-blind trial on 3494 patients with OAB demonstrated 
that combination of mirabegron (25 mg) or mirabegron (50 mg) and solifenacin (5 mg) is correlated 
with clear improvements in urinary symptoms and treatment satisfaction compared with mirabegron 
and solifenacin as monotherapies. [90] 
However, there is concern that combination of these drugs could also have a synergistic effect on heart 
receptors and could theoretically lead to exacerbation of CV side effects especially in old patients with 
CV comorbidities. The BESIDE study, a randomized double-blind study, was the first to investigate CV 
safety in OAB patients treated with a combination of mirabegron and solifenacin. It has shown that the 
frequency of CV AEs and changes in vital sign and ECG parameters were comparable between 
solifenacin alone (5 mg or 10 mg) and in combination with mirabegron thus demonstrating the lack of 
synergistic effect on heart tissue [91]. This was confirmed by another recent study [67] that investigated 
the efficacy and safety of combining mirabegron and solifencin. It demonstrated that the combination 
of these drugs at low doses can improve the tolerability profile in comparison with monotherapy, 
without compromising efficacy. This study also demonstrated no supra-additive effects on safety 
parameters. There was no dose-related difference in PR or BP between combination and single 
therapies with them. The fact that fewer AEs occurred on combination therapy than on  solifenacin at 
10 mg as monotherapy, in addition to the absence of clinically significant additive AEs in terms of 
hypertension and PR, suggests that this twice therapy may offer benefits in patients intolerant to AM 
dose escalation requiring additional efficacy. 
A recent phase III study has demonstrated that vibegron, a novel potent selective β3 agonist, is 
clinically useful and safe for the treatment of patients with OAB. Furthermore vibegron, differently 
from mirabegron, did not show any induction and inhibitory effect on cytochrome (CYP) enzymes 
suggesting no risk of drug-drug interaction [92]. 
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On the basis of this considerations, combinatory therapies of vibegron and AMs were tested in an 
interesting study of Di Salvo et al. [93]. In female Rhesus monkeys, the authors showed that by 
combining vibegron with AMs bladder relaxation improved. Moreover, it was found a better synergism 
when both M2 and M3-subtypes receptors were blocked. Indeed, this effect was greater with 
tolterodine than with darifenacin, a selective M3 receptor blocker. Although M2-subtype has only an 
indirect role in bladder relaxation, its inhibition leads to a greater effect of β3 agonist, by increasing 
cyclic adenosine monophosphate (cAMP). 
 
5.Conclusions 
While AMs are the most commonly used drugs in the context of OAB, the β3 agonist mirabegron 
constitutes a valid alternative.  As OAB syndrome often affects elderly people, who may present CV 
comorbidities, and because the drugs prescribed may interact with receptors present both in the urinary 
and CV systems, the cardiologic consequences of the use of AMs and mirabegron have aroused great 
interest.  The most common consequences of AMs use may be an increase in HR and QT interval.  
Increased HR may be associated with the use of fesoterodine, propiverine, tolderodine and trospium, 
while the other AMs do not present this AE. Various studies have reported that QT interval is not 
prolonged by AMs. Indeed, only three cases of QT prolongation and TdP have been reported with the 
use of solifenacin (5 mg or 10 mg/die) in women > 80 years of age. QT prolongation must be taken into 
consideration when AMS are prescribed in females, particularly if they are elderly. Furthermore, 
interactions between AMs and drugs that compete for the same pathway, such as hepatic metabolism 
through cytochrome P450, may take place, thereby increasing QT. On the other hand, mirabegron, a 
selective β-3 agonist constitutes a good alternative for the treatment of OAB. This systematic review 
has shown that mirabegron presents similar efficacy and tolerability to AMs in phase II and III trials. 
Moreover, fewer AEs are reported, and these disappear on the discontinuation of the treatment. The 
most commonly reported AEs are either modest hypertension or a slight increase in HR. Unfortunately, 
long-term data are needed in order to confirm the CV safety and efficacy of mirabegron [42]. 
Furthermore, the combination of mirabegron and an AM drug such as solifenacin at low doses may be 
considered safe, without causing clinically significant additive effects in terms of hypertension and PR.   
 
6. Expert opinion 
AMs drugs are the most commonly prescribed drugs for OAB, however long-term compliance is low 
due to perceived lack of efficacy and AEs. CV AEs are rare but noteworthy, are mainly reported in 
Ac
ce
pte
d M
an
us
cri
pt
women who are more prone to develop QT prolongation, particularly if elderly. On the other hand, 
cardiac AEs has not to be necessarily attributed only to the drug itself but to the metabolic effects of the 
co-administered drug, which may increase the plasmatic levels of the agent. In conclusion, the CV 
safety profile of AMs seems to be good but an increase in HR and a prolongation of QT cannot be 
excluded as well as an increase in CV risk due to drug-drug interactions in old patients who present 
various comorbidities.  
Conversely, mirabegron, a β3-adrenoceptor agonist has shown similar efficacy and tolerability but 
reduced AEs. Hypertension was the most commonly reported AE associated with the administration of 
mirabegron but the increase of systolic blood pressure/diastolic blood pressure (SBP/SDP) was trivial 
and reversible upon treatment discontinuation. Furthermore, in all the studies there was no evidence of 
risk for the occurrence of severe CV AEs in all patients receiving mirabegron at all doses. 
Furthermore, for AMs most data on patients with poorly controlled hypertension, arrhythmias or 
cardiac heart failure are currently missing because these patients are often excluded from clinical trials 
utilizing these drugs. For what regards mirabegron, more recent studies have provided a larger amount 
of data from real-world and all these studies confirm its efficacy and safety [79, 81]. 
Irrespective of the mechanism of action the clinical CV profile of mirabegron, when used at the 
recommended dose, gives no reason for alarm. Moreover, by combining mirabegron with a AM, the 
CV AEs may be further reduced. 
In our opinion, despite the safe pharmacological profile of AMs and mirabegron, a clinical and ECG 
monitoring might be necessary throughout the administration period in selected patients such as those 
aged> 80 years, those with coronary heart disease or congestive heart failure. In these patients, 
according to a recent consensus written by the American College of Cardiology, HR independently 
predicts outcomes so we have to be very cautious about using drugs causing tachycardia [94]. 
Unfortunately, a standardized clinical surveillance is difficult to recommend on the basis of the limited 
knowledge available from current literature 
We hope that research will be oriented towards investigating the effects of long-term treatment with 
AMs or mirabegron on CV function in particular sub-populations of patients, such as the very elderly 
and those with CV disease. Furthermore, research should investigate the safety and efficacy of the 
newest and most selective AMs, such as imidafenacin and solifenacin, not only if taken singly but also, 
and especially, if associated with mirabegron.  
According with recent studies, vibegron, a new potent β3 agonist, is clinically useful and safe in the 
treatment of patients with OAB, furthermore it does not interact with CYP enzymes. A direct head to 
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head study comparing efficacy and safety of mirabegron and vibegron is required, furthermore we hope 
that future research will better investigate the safety and the efficacy of combination therapy with 
vibegron and AMs.   
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Tables  
 
Table 1. Summary of the cardiovascular adverse effects of AM drugs 
 HR HRV QTc BP 
Darifenacine 
Hydrobromide 
No significant 
change is 
reported[60,61] 
No significant 
change is 
reported [60,61] 
No significant 
change is 
reported neither 
in poor 
metabolizers[59] 
NA 
Fesoterodine 
fumarate 
dose related 
increase (≤ 4 
bpm) [54,55] 
No significant 
change is 
reported [54,55] 
No significant 
change is 
reported [54,55] 
No significant 
change is 
reported[54,55] 
Tolterodine 
taltrate 
increase of 3 
bpm [52] 
increase of 10 
bpm with 8 mg 
dosage[53]  no 
Relevant effect at 
supraterapeutic 
dose, slight effect 
with 4 mg in 
healthy subjects, 
No significant 
change is 
reported 
[83,85,86] 
No significant 
change is 
reported 
[83,85,86] 
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significant 
increase with ER 
preparation 
[51,83,86] 
relevant in 
patients with 
OAB [51-53] 
Trospium 
chloride 
Increase of 14 
bpm for  i.v 
preparation  , not 
relevant for oral 
use [58] 
NA No significant 
change is 
reported [58] 
NA 
Oxybutynin 
chloride 
No significant 
change is 
reported [56,61] 
No significant 
change is 
reported [56,61] 
No significant 
change is 
reported [77] 
NA 
Propiverine 
hydrochloride 
increase of 4.4 
bpm[62] 
Reduction [56] QTprolongation 
but no 
increase >500 
msec; no increase 
in healthy 
women [76] 
NA 
Solifenacin 
succinate 
No effect [56,87] NA Three cases of 
TdP [68,69,70] 
small increase of 
QTc [66,67] 
No effect [56,87] 
Imidafenacin Not significant 
[62] 
NA Not significant 
[62] 
NA 
 
HR= heart rate; HRV= heart rate variability; BP=Blood pressure; NA= no data available; bpm= beats 
per minute 
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Table 2. Change from baseline in Pulse rate and tachycardia events 
 PR AM 
(bpm) 
mean 
change 
from 
baseline 
ƚ 
PR PM (bpm) mean 
change from baseline ƚ 
PR (bpm) mean change 
from baseline ǂ 
Tachycardia incidence 
N (%) # 
Pooled 12 week phase III 
Placebo (n=1380) 
Mirabegron 25 mg (n=432) 
Mirabegron 50 mg (n=1375) 
Mirabegron 100 mg (n=929) 
0.4 
1.3 
1.4 
2.3 
-0.4 
0.2 
0.6 
1.9 
NA 43 (3.1) 
21 (4.9) 
52 (3.8) 
43 (4.6) 
BEYOND
Mirabegron 50 mg (n=936) NA NA 0.5 17 (1.8) 
TAURUS
Mirabegron 50 mg (n=812) 
Mirabegron 100 mg (n=820) 
0.9 
1.6 
0.4 
1.3 
NA NA 
BLOSSOM
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Placebo 
Mirabegron 100 mg BID (n=65) 
Mirabegron 150 MG BID (n=65) 
NA NA  
5 
-0.7 
NA 
DRAGON
Placebo (n=166) 
Mirabegron 25 mg (n=167) 
Mirabegron  50 mg (n=167) 
Mirabegron 100 mg (n=168) 
Mirabegron 200 mg (n=168) 
0.51 
0.3 
1.6 
2.2 
4.7 
-0.04 
0.4 
1.1 
2.7 
4.7 
NA NA 
 
PR=Pulse rate; ƚ measured by patients and reported on diary; ǂ measured at visit; # based on TEAE or asymptomatic PR measure by 
patients>100 bpm; NA= no data available; BID=twice day 
 
Table 3. Change from baseline in blood pressure and hypertensive events 
 SBP AM 
(bpm) 
mean 
change 
from 
SPM PM 
(bpm) 
mean 
change 
from 
DBP AM 
(bpm) mean 
change from 
baseline ƚ 
DBP PM 
(bpm) mean 
change from 
baseline ƚ 
SBP at visit 
(mmHg) ǂ 
DBP at visit 
(mmHg) ǂ 
Hypertension 
events N (%)ǂ 
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baseline 
ƚ 
baseline ƚ 
Pooled 12 week phase III 
Placebo (n=1380) 
Mirabegron 25 mg 
(n=432) 
Mirabegron 50 mg 
(n=1375) 
Mirabegron 100 mg 
(n=929) 
0.2 
0.3 
0.8 
0.6 
0.6 
-0.5 
1.1 
1.4 
0 
-0.1 
0.4 
0.2 
0 
0.1 
0.7 
0.9 
NA NA 105 (7.6) 
49 (11.3) 
103 (7.5) 
48 (5.2) 
BEYOND
Mirabegron 50 mg 
(n=916) 
NA NA NA NA 0.7 0.7 10 (1.1) 
TAURUS       
Mirabegron 50 mg 
(n=812) 
Mirabegron 100 mg 
(n=820) 
0.2 
0.4 
-0.3 
0.1 
-0.3 
0.4 
0 
0.1 
NA NA NA 
12 week phase III Asian trial 
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Mirabegron 50 mg 
(n=366) 
-1.38# NA 1.82# NA NA NA 2 (0.5) 
 
SBP=systolic blood pressure; DBP=diastolic blood pressure; ƚ measured by patients and reported on diary; ǂ measured at visit; # mean 
difference from placebo; NA= no data available 
 
Table 4. Number of patients with QTcF changes from baseline 
 QTcF>450 
ms N (%) 
QTcF>480 
ms N (%) 
QTcF>500 ms N 
(%) 
QTcF>30 ms N (%) QTcF>60 ms N (%)
TAURUS 
Mirabegron 50 mg (n=812) 
Mirabegron 100 mg (n=820) 
36 (4.9) 
29 (3.9) 
5 (0.7) 
2 (0.3) 
2 (0.3) 
1 (0.1) 
76 (10) 
67 (9.0) 
3 (0.4) 
3 (0.4) 
Pooled 12 week phase III studies
Placebo (n=1380) 
Mirabegron 25 mg (n=432) 
Mirabegron 50 mg (n=1375) 
Mirabegron 100 mg (n=929) 
44 (3.5) 
14 (3.4) 
32 (2.6) 
27 (3.2) 
3 (0.2) 
0 
3 (0.2) 
5 (0.6) 
1 (0.1) 
0 
0 
1 (0.1) 
44 (3.6) 
9 (2.2) 
54 (4.3) 
24 (2.9) 
2 (0.2) 
1 (0.2) 
1 (0.1) 
2 (0.2) 
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QTcF=QTc interval measured using Fridericia correction method 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
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